

| | | | |
|--|--|---|--------------------------------------|
| Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | U.S. Department of Commerce Patent and Trademark Office | Attorney Docket No. 22862-0003US1 | Application No. 10/598,486 |
| | Applicant Yu et al. | | |
| | Filing Date August 31, 2006 | Group Art Unit 1644 | |

U.S. Patent Documents

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|-----------------|-------|----------|----------------------------|
| | 1 | 5,844,075 | 12/01/1998 | Kawakami et al. | | | |
| | 2 | 6,010,905 | 01/04/2000 | Cohen et al. | | | |
| | 3 | 2002/0182194 | 12/05/2002 | Ju et al. | | | |
| | 4 | 2003/0064916 | 04/03/2003 | Sherman | | | |
| | 5 | 2010/0135975 | 06/03/2010 | Yu et al. | | | |
| | 6 | 2010/0310643 | 12/09/2010 | Singh et al. | | | |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| | 7 | WO 2006/034334 | 03/30/2006 | WIPO | | | | |
| | 8 | WO 2010/028066 | 03/11/2010 | WIPO | | | | |
| | 9 | WO 2010/129895 | 11/11/2010 | WIPO | | | | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|------------------|-----------|--|
| | 10 | ABDEL-WAHAB et al., "Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity," Cell. Immunol., 186:63-74 (1998) |
| | 11 | BODEY et al., "Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors," In Vivo, 20:519-525 (2006) |
| | 12 | CASEY et al., "Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine," Immunology, 110:105-111 (2003) |
| | 13 | CHO et al., "Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas," Cell Transplant., 18:977-983 (2009) |
| | 14 | CZERNIECKI et al., "Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion," Cancer Res., 67:1842-52 (2007) |
| | 15 | DAUER et al., "Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells," J. Immunother., 28:332-342 (2005) |
| | 16 | DENKERT et al., "Prognostic impact of cyclooxygenase-2 in breast cancer," Clin. Breast Cancer, 4:428-433 (2004) |
| | 17 | GASPARINI et al., "Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?" Lancet Oncol., 4:605-615 (2003) |
| | 18 | IRVIN et al., "T cells enhance stem-like properties and conditional malignancy in gliomas," PLoS One, 5:e10974 (2010) |
| | 19 | KUBY et al., Immunology, W. H. Freeman and Co., pp. 523-524 (1992) |

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AJ/

| | | | |
|---|--|---|--------------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney Docket No. 22862-0003US1 | Application No. 10/598,486 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) | | Applicant Yu et al. | |
| | | Filing Date August 31, 2006 | Group Art Unit 1644 |
| (37 CFR §1.98(b)) | | | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|--|
| Examiner Initial | Desig. ID | Document |
| | 20 | LEFRANC, "Editorial: On the road to multi-modal and pluri-disciplinary treatment of glioblastomas," Acta Neurochir. (Wien), 151:109-112 (2009) |
| | 21 | LIAO et al., "Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?" Drugs, 67:821-845 (2007) |
| | 22 | LIU et al., "Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma," Mol. Cancer, 5:67 (2006) |
| | 23 | LIU et al., "Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma," Cancer Control, 10:138-147 (2003) |
| | 24 | LIU et al., "Chemoresistance of stem-like cells isolated from glioblastoma," Proc. Amer. Assoc. Cancer Res., 47:75, abstract #320 (2006) (cited in 22862-0006EP1) |
| | 25 | LIU et al., "AIM-2: a novel tumor antigen is expressed and presented by human glioma cells," J. Immunother., 27:220-226 (2004) |
| | 26 | LIU et al., "HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells," Cancer Res., 64:4980-86 (2004) |
| | 27 | MELCHER et al., "Dendritic cells for the immunotherapy of cancer," Clin. Oncol., 14:185-192 (2002) |
| | 28 | OGINO et al., "Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer," Clin. Cancer Res., 14:8221-27 (2008) |
| | 29 | OHNO et al., "Multiple roles of cyclooxygenase-2 in endometrial cancer," Anticancer Res., 25:3679-87 (2005) |
| | 30 | PARMIANI et al., "Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?" J. Natl. Cancer Inst., 94:805-818 (2002) |
| | 31 | PARNEY et al., "Glioma immunology and immunotherapy," Neurosurgery, 46:778-791 (2000) |
| | 32 | SOLING et al., "Dendritic cell therapy of primary brain tumors," Mol. Med., 7:659-667 (2001) |
| | 33 | SOUMAORO et al., "Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer," Clin. Cancer. Res., 10:8465-71 (2004) |
| | 34 | TAKAGI et al., "Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells," Cancer Lett., 213:49-55 (2004) |
| | 35 | WESTPHAL et al., "Other experimental therapies for glioma," Recent Results Cancer Res., 171:155-164 (2009) |
| | 36 | YANG et al., "Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme," J. Neurosurg., 100:310-319 (2004) |
| | 37 | YOUNG et al., "Cyclooxygenase-2 in cervical neoplasia: a review," Gynecol. Oncol., 109:140-145 (2008) |
| | 38 | YUAN et al., "Isolation of cancer stem cells from adult glioblastoma multiforme," Oncogene, 58:9392-9400 (2004) |
| | 39 | ZAGZAG et al., "Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain," Lab. Invest., 85:328-341 (2005) |

| | | | |
|--|--------------|-----------------|------------|
| Examiner Signature | /Amy Juedes/ | Date Considered | 05/11/2011 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |